Sector News

Will docs jump on new biosims? Survey shows they’ll need some nudging

August 17, 2015
Life sciences
Drugmakers are well aware of the biosimilars threatening to steal sales and market share from some of the world’s best-selling biologics.
 
Doctors, though? Not so much, a new report suggests.
 
Doctor platform and community QuantiaMD recently surveyed 300 primary care physicians and specialists to find out just how much healthcare providers knew about the drugs. 78% of those polled said they were familiar with the term “biosimilar,” but only 38% could name one under consideration for FDA approval that would be relevant to their patients, Medical Marketing & Media report.
 
To make matters worse, only 17% of the doctors Quantia deemed most likely to prescribe biologics–and, thus, the most likely to prescribe biosimilars in the future–said they were “very likely” to do so. 70% said they either weren’t sure or were “somewhat likely” to write a biosimilar script.
 
That’s a problem for the copycat pharmas looking to steal a piece of the pie from blockbusters like Amgen’s Neupogen, AbbVie’s Humira and Johnson & Johnson’s Remicade. Whether biosimilars pick up steam will largely depend on doctors–and on their likelihood to order them for patients.
 
Right now, only one biosimilar has FDA approval, and that’s Zarxio, a Novartis copy of Neupogen that won’t roll out until September, per court orders.
 
In the meantime, though, what can drugmakers do to get the word out to docs? “There’s a lot of opportunity for education,” Rachel Daricek, QuantiaMD’s senior director of client services, told MM&M. ” … They haven’t seen any efficacy and safety data or seen any communication from pharma or their organization–they don’t know what to think.”
 
By Carly Helfand
 

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend